154 related articles for article (PubMed ID: 1701918)
21. Peptide handling by HLA-B27 subtypes influences their biological behavior, association with ankylosing spondylitis and susceptibility to endoplasmic reticulum aminopeptidase 1 (ERAP1).
García-Medel N; Sanz-Bravo A; Alvarez-Navarro C; Gómez-Molina P; Barnea E; Marcilla M; Admon A; de Castro JA
Mol Cell Proteomics; 2014 Dec; 13(12):3367-80. PubMed ID: 25187574
[TBL] [Abstract][Full Text] [Related]
22. Unusual topology of an HLA-B27 allospecific T cell epitope lacking peptide specificity.
Villadangos JA; Galocha B; López de Castro JA
J Immunol; 1994 Mar; 152(5):2317-23. PubMed ID: 7510742
[TBL] [Abstract][Full Text] [Related]
23. Conformational Plasticity of HLA-B27 Molecules Correlates Inversely With Efficiency of Negative T Cell Selection.
Loll B; Rückert C; Uchanska-Ziegler B; Ziegler A
Front Immunol; 2020; 11():179. PubMed ID: 32117305
[TBL] [Abstract][Full Text] [Related]
24. HLA-B27 and antigen presentation: at the crossroads between immune defense and autoimmunity.
Sorrentino R; Böckmann RA; Fiorillo MT
Mol Immunol; 2014 Jan; 57(1):22-7. PubMed ID: 23916069
[TBL] [Abstract][Full Text] [Related]
25. Asymmetric selection of T cell antigen receptor alpha- and beta-chains in HLA-B27 alloreactivity.
Lauzurica P; Bragado R; López D; Galocha B; López de Castro JA
J Immunol; 1992 Jun; 148(11):3624-30. PubMed ID: 1316921
[TBL] [Abstract][Full Text] [Related]
26. Subtypes of HLA-B27: history and implications in the pathogenesis of ankylosing spondylitis.
Reveille JD; Maganti RM
Adv Exp Med Biol; 2009; 649():159-76. PubMed ID: 19731628
[TBL] [Abstract][Full Text] [Related]
27. HLA-B27 and the seronegative spondyloarthropathies.
Reveille JD
Am J Med Sci; 1998 Oct; 316(4):239-49. PubMed ID: 9766485
[TBL] [Abstract][Full Text] [Related]
28. The naturally occurring polymorphism Asp116-->His116, differentiating the ankylosing spondylitis-associated HLA-B*2705 from the non-associated HLA-B*2709 subtype, influences peptide-specific CD8 T cell recognition.
Fiorillo MT; Greco G; Maragno M; Potolicchio I; Monizio A; Dupuis ML; Sorrentino R
Eur J Immunol; 1998 Aug; 28(8):2508-16. PubMed ID: 9710228
[TBL] [Abstract][Full Text] [Related]
29. Clonal analysis of alloreactive T cell responses against the closely related B*2705 and B*2703 subtypes. Implications for HLA-B27 association to spondyloarthropathy.
López D; García-Hoyo R; López de Castro JA
J Immunol; 1994 Jun; 152(11):5557-71. PubMed ID: 8189072
[TBL] [Abstract][Full Text] [Related]
30. HLA-B27 presents a peptide from a polymorphic region of its own molecule with homology to proteins from arthritogenic bacteria.
García F; Marina A; Albar JP; López de Castro JA
Tissue Antigens; 1997 Jan; 49(1):23-8. PubMed ID: 9027961
[TBL] [Abstract][Full Text] [Related]
31. Structure of class-I MHC molecules: HLA-B27 and disease.
Parham P
Scand J Rheumatol Suppl; 1990; 87():11-20. PubMed ID: 2259878
[TBL] [Abstract][Full Text] [Related]
32. Structural analysis of an HLA-B27 functional variant: identification of residues that contribute to the specificity of recognition by cytolytic T lymphocytes.
Vega MA; Ezquerra A; Rojo S; Aparicio P; Bragado R; López de Castro JA
Proc Natl Acad Sci U S A; 1985 Nov; 82(21):7394-8. PubMed ID: 2414775
[TBL] [Abstract][Full Text] [Related]
33. Molecular mimicry between human leukocyte antigen B27 and Klebsiella. Consequences for spondyloarthropathies.
Schwimmbeck PL; Oldstone MB
Am J Med; 1988 Dec; 85(6A):51-3. PubMed ID: 2462350
[TBL] [Abstract][Full Text] [Related]
34. T cell receptor diversity in alloreactive responses against HLA-B27 (B*2705) is limited by multiple-level restrictions in both alpha and beta chains.
Barber DF; López D; López de Castro JA
Eur J Immunol; 1995 Sep; 25(9):2479-85. PubMed ID: 7589114
[TBL] [Abstract][Full Text] [Related]
35. T cell receptor V beta gene usage in a human alloreactive response. Shared structural features among HLA-B27-specific T cell clones.
Bragado R; Lauzurica P; López D; López de Castro JA
J Exp Med; 1990 Apr; 171(4):1189-204. PubMed ID: 1691261
[TBL] [Abstract][Full Text] [Related]
36. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis.
D'Amato M; Fiorillo MT; Carcassi C; Mathieu A; Zuccarelli A; Bitti PP; Tosi R; Sorrentino R
Eur J Immunol; 1995 Nov; 25(11):3199-201. PubMed ID: 7489765
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel HLA-B27 ligands derived from polymorphic regions of its own or other class I molecules based on direct generation by 20 S proteasome.
Alvarez I; Sesma L; Marcilla M; Ramos M; Marti M; Camafeita E; de Castro JA
J Biol Chem; 2001 Aug; 276(35):32729-37. PubMed ID: 11435436
[TBL] [Abstract][Full Text] [Related]
38. Changes in the repertoire of peptides bound to HLA-B27 subtypes and to site-specific mutants inside and outside pocket B.
Rojo S; García F; Villadangos JA; López de Castro JA
J Exp Med; 1993 Mar; 177(3):613-20. PubMed ID: 8436905
[TBL] [Abstract][Full Text] [Related]
39. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.
Brooks JM; Murray RJ; Thomas WA; Kurilla MG; Rickinson AB
J Exp Med; 1993 Sep; 178(3):879-87. PubMed ID: 7688791
[TBL] [Abstract][Full Text] [Related]
40. HLA-B27 and HLA-B73 polymorphism and its role on antigenicity, peptide presentation, and disease susceptibility.
Lopez De Castro JA
Clin Rheumatol; 1996 Jan; 15 Suppl 1():67-71. PubMed ID: 8835507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
